Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil

“…This study's results suggest the benefit of PCV10 in reducing the incidence of pneumococcal meningitis, since the current literature refers to the impact of PCV7 used in other countries, with differences in the composition compared to PCV10, the latter with the addition of three more serotypes: 1, 5, and 7F. In Finland, results of a randomized clinical trial showed 92% and 100% efficacy rates for PCV10 using vaccination schemes of 2+1 and 3+1 doses, respectively 26 . In Quebec, PCV7 was replaced by PCV10 five years after the former was introduced, and the data show lower incidence of invasive pneumococcal disease in children vaccinated with PCV10 compared to PCV7 27 .…”

Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial

“…5 The trial design has been previously described. 4 Briefly, children younger than 19 months could be enrolled if they had not received and were not anticipated to receive any of the study vaccines and had no general contraindications to vaccinations.…”

“…The treatment was allocated into the 78 clusters (2:2:1:1) into PHiD-CV10 three plus one, PHiD-CV10 two plus one, control three plus one, and control two plus one groups (26:26:13:13 clusters) and stratified according to the birth cohort size (lower or higher than average), TAUVRC trial enrolment (50 of 78 clusters), and urbanity (24 urban and 54 rural clusters). 4 Details of the masking have been presented previously. 4 …”

“…4 To estimate the effect of pneumococcal conjugate vaccines on invasive pneumococcal disease more comprehensively taking into account the potential suboptimum sensitivity of laboratory-based detection, we set to assess vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10, Synflorix, GlaxoSmithKline, Belgium) against clinically suspected invasive pneumococcal disease with hospital discharge register data.…”

A few years later

“…[4][5][6][7][8] In addition, new efficacy and effectiveness data have been published, which were not available at that time. [9][10][11][12][13] This study aimed to calculate the cost-effectiveness of PCV13 compared with PCV10 using the newly available data. Our study was performed to inform the Dutch Health Council, which has advised the Ministry of Health for a new tender, worth approximately 530 000 doses per year, that took place in the beginning of 2014.…”